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Pathognomonic PAX3-FOXO1 fusion oncogene expression is associated with poor 
outcome in rhabdomyosarcoma. Combining genome-wide CRISPR screening with cell-
based functional genetic approaches, we here provide evidence that PAX3-FOXO1 
induces replication stress, resulting in a synthetic lethal dependency to ATR-mediated 
DNA damage-response signaling in rhabdomyosarcoma. Expression of PAX3-FOXO1 in 
muscle progenitor cells was not only sufficient to induce hypersensitivity to ATR 
inhibition, but PAX3-FOXO1-expressing rhabdomyosarcoma cells also exhibited 
increased sensitivity to structurally diverse inhibitors of ATR, a dependency that could 
be validated genetically. Mechanistically, ATR inhibition led to replication stress 
exacerbation, decreased BRCA1 phosphorylation and reduced homologous 
recombination-mediated DNA repair pathway activity. Consequently, ATR inhibitor 
treatment increased sensitivity of rhabdomyosarcoma cells to PARP inhibition in vitro, 
and combined ATR and PARP inhibition induced regression of primary patient-derived 
alveolar rhabdomyosarcoma xenografts in vivo. Moreover, a genome-wide CRISPR 
activation screen (CRISPRa) identified FOS gene family members as inducers of 
resistance against ATR inhibitors. Mechanistically, FOS gene family members reduced 
replication stress in rhabdomyosarcoma cells. Lastly, compassionate use of ATR 
inhibitors in two pediatric patients suffering from relapsed PAX3-FOXO1-expressing 
alveolar rhabdomyosarcoma showed signs of tolerability, paving the way to clinically 
exploit this novel synthetic lethal dependency in rhabdomyosarcoma. 
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Rhabdomyosarcomas are the most common soft tissue tumors in childhood1. Whereas the 
majority of rhabdomyosarcomas are histologically classified as embryonal 
rhabdomyosarcoma (ERMS), about 25% of cases present as alveolar rhabdomyosarcoma 
(ARMS) and harbor pathognomonic chromosomal translocations involving genes 
encoding for the PAX3 (and less frequently, PAX7) and FOXO1 transcription factors2,3. 
PAX3/7-FOXO1 expression is not only sufficient to drive tumorigenesis4, but is also 
associated with adverse clinical outcome. Patients harboring PAX3/7-FOXO1-expressing 
rhabdomyosarcomas often develop metastases and/or resistance to chemotherapy during 
the course of disease5. Despite advances in targeted cancer therapy development, no new 
pharmacological treatment options have been clinically approved for metastatic or 
recurrent rhabdomyosarcomas in the last ~30 years6. It is widely accepted that current 
treatment strategies have reached their limits. To overcome these limits, new 
therapeutically actionable disease mechanisms need to be identified. However, PAX3/7-
FOXO1-driven rhabdomyosarcomas are rarely associated with therapeutically actionable 
genetic aberrations7. Thus, the identification of new therapeutic strategies for high-risk 
PAX3/7-FOXO1-expressing rhabdomyosarcoma remains challenging. 
Most cancers depend on active DNA damage repair, explaining why genotoxic agents are 
among the most effective chemotherapeutic agents in cancer therapy8. The therapeutic 
window of genotoxic agents, however, is often narrow and considerable long-term 
sequelae occur in patients treated with such agents. Synthetic lethal cellular dependencies 
have emerged as tumor-specific vulnerabilities, which provide therapeutic targets 
offering much broader therapeutic windows9. In particular, DNA damage response 
(DDR) pathway dependencies are being successfully exploited for the development of 
novel therapies. As a prototypical example, BRCA1 deficient tumors rely on PARP-
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mediated base-excision DNA repair (BER), a synthetic lethal relationship that was 
clinically translated in breast and ovarian cancers among other tumor entities10,11. Thus, 
exploiting DDR pathway dependencies may enable the development of novel therapeutic 
strategies for rhabdomyosarcomas.  
Oncogenes, particularly those encoding for transcription factors and fusion transcription 
factors, can interfere with the normal function of the DNA replication machinery through 
massive deregulation of transcriptional activity12. Resulting transcription-induced 
replication fork stalling leads to activation of DDR pathways, during which unprotected 
single stranded DNA is bound by Replication Protein A (RPA32), subsequently recruiting 
the ataxia telangiectasia and Rad3 related (ATR) kinase13-16. This process has been termed 
oncogene-induced replication stress. Upon recognition of the DNA break, ATR activates 
checkpoint kinase 1 (CHK1) among other factors to stop cells from cycling and to 
coordinate DNA repair17. Unsurprisingly, many tumors depend on ATR activity to 
proliferate in the presence of oncogene-induced replication stress. Based on this 
observation, ATR has become a candidate target for pharmacological inhibition in cancer 
therapy. Even though some molecular features create synthetic lethal ATR dependencies, 
including ATM and TP53 loss, MYC proto-oncogene expression, EWS-FLI1 fusion 
oncogene expression and PGBD5 expression18-26, the mechanisms driving response to 
ATR inhibition in most cancer entities are still largely unknown. Here, we show that 
PAX3-FOXO1 expression renders highly aggressive alveolar rhabdomyosarcomas 
sensitive to ATR inhibition in vitro and in vivo, revealing a novel and clinically 
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Alveolar rhabdomyosarcoma cell lines genetically depend on ATR and are 
hypersensitive to pharmacological ATR pathway inhibition 
To identify therapeutically actionable DNA damage repair pathway vulnerabilities in 
alveolar rhabdomyosarcomas, we inquired the publicly available database, DepMap27 , 
focusing on pharmacologically targetable DDR pathway members ATR, ATM, CHK1 
and CHK2 (Fig. 1a and Extended data Fig. 1a-c). Whereas ATM and CHK2 depletion via 
CRISPR-Cas9 did not lead to significant survival disadvantage in rhabdomyosarcoma 
cell lines, depletion of ATR and CHK1 was strongly selected against, as evidenced by 
low dependency scores (Fig. 1a and Extended data Fig. 1a). Intriguingly, alveolar 
rhabdomyosarcoma cells were amongst the most dependent on ATR (Fig. 1a). To test if 
this genetic dependency could translate into sensitivity towards pharmacological ATR 
inhibition, we incubated a panel of nine rhabdomyosarcoma cell lines, all of which 
expressed ATR and CHK1 (Extended data Fig. 1d-e), with structurally diverse ATR- 
(AZD6738, BAY-1895344, VE-822), ATM- (AZD0156, KU60019) and CHK1/2-
specific (AZD7762) small molecule inhibitors (Fig. 1b-e and Extended data Fig. 2a-h). 
Rhabdomyosarcoma cell lines showed varying degrees of sensitivity to small molecule-
mediated ATR, ATM and CHK1/2 inhibition, with inhibitory concentrations (IC50) 
ranging between 50 nM and 10 µM (Extended data Fig. 2i). In line with greater genetic 
dependency towards ATR (Fig. 1a), alveolar rhabdomyosarcoma cell lines were 
significantly more sensitive to ATR inhibition by three structurally diverse small 
molecule ATR inhibitors AZD6738, VE-822 and BAY-1895344 than embryonal 
rhabdomyosarcoma cells (Fig. 1b-e and Extended data Fig. 2a-b). This increased 
sensitivity was also observed for CHK1/2 inhibitor AZD7762 (Extended data Fig. 2c-d), 
indicating that alveolar rhabdomyosarcoma cells depend on active ATR pathway 
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signaling. In line with an ATR pathway-specific dependency, no difference in sensitivity 
between alveolar and embryonal rhabdomyosarcoma cells was observed for ATM 
inhibitors KU60019 and AZD0156 (Extended data Fig. 2e-h). Thus, alveolar 
rhabdomyosarcoma cells depend on ATR, rendering them hypersensitive to 
pharmacological ATR pathway inhibition.  
ATR inhibition leads to replication stress, genomic instability, apoptosis and cell cycle 
disruption in alveolar rhabdomyosarcoma cells  
ATR is a key regulator of replication stress and genomic stability28. We hypothesized that 
high steady-state replication stress and genomic instability may cause sensitivity of 
alveolar rhabdomyosarcoma cells to ATR inhibition. Once recruited to single stranded 
DNA bound by RPA32 during replication stress, ATR phosphorylates RPA32 at T21 and 
S3329. To test the association between steady-state replication stress and ATR inhibitor 
sensitivity, we measured RPA32 phosphorylation at T21 and S33 in rhabdomyosarcoma 
cell lines using western immunoblotting. Indeed, high levels of RPA32 phosphorylation 
were observed in alveolar rhabdomyosarcoma cell lines (Fig. 2a-b). In line with higher 
replication stress, a higher fraction of alveolar rhabdomyosarcoma cells presented 
micronuclei (Fig. 2c-d), a sign of genomic instability associated with replication stress30. 
This suggested that alveolar rhabdomyosarcoma cells either had critically high DNA 
damage levels or lacked intrinsic DNA damage repair activity to resolve such damage. 
To distinguish between these possible mechanisms, we assessed the endogenous activity 
of two major DNA damage repair mechanisms, non-homologous end-joining repair 
(NHEJ) and homologous recombination (HR), across rhabdomyosarcoma cell lines. No 
significant difference in NHEJ and HR activity was observed between alveolar and 
embryonal rhabdomyosarcoma cell lines (Fig. 2e and Extended data Fig. 3a-d), 
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suggesting that differences in endogenous DNA damage levels rather than repair activity 
may drive the observed differences in steady-state genomic instability.  
We hypothesized that ATR inhibition may lead to exacerbation of replication stress and 
genomic instability, i.e. an increase in the severity above a tolerable point, specifically in 
alveolar rhabdomyosarcoma cells. Indeed, RPA32 S33 and T21 phosphorylation 
increased after treatment with AZD6738 in all cell lines tested (Fig. 3a and Extended data 
Fig. 3e-f) and was accompanied by an increase in micronucleated cells (Fig. 3b and 
Extended data Fig. 3g), in particular in alveolar rhabdomyosarcoma cells. Co-staining 
with 5-Ethynyl-2´-deoxyuridine (EdU) and propidium iodide (PI) after incubation with 
ATR inhibitors revealed that alveolar rhabdomyosarcoma cells accumulated in G2/M-
phase with a corresponding reduction of cells in S-phase, indicating a bypass of intra-S 
phase cell cycle checkpoint (Fig. 3c and Extended data Fig. 3g). In contrast, embryonal 
rhabdomyosarcoma cells’ cycling was almost unperturbed (Fig. 3c). Consistent with the 
increased ATR dependency (Fig. 1a), alveolar rhabdomyosarcoma cells showed 
significant accumulation of unrepaired DNA double stranded breaks when treated with 
an ATR inhibitor, as measured by terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL; Fig. 3d and Extended data Fig. 3h). Furthermore, increased cell death, 
as measured by Caspase 3 cleavage, was more pronounced in alveolar compared to 
embryonal rhabdomyosarcoma cells incubated in the presence of an ATR inhibitor (Fig. 
3e and Extended data Fig. 3i). Lastly, the fraction of aneuploid cells significantly 
increased after ATR inhibition (Fig. 3f and Extended data Fig. 3j), suggesting 
chromosome missegregation due to erroneous repair of unresolved replication 
intermediates. Based on this, we propose that ATR inhibition exacerbates replication 
stress, in particular in alveolar rhabdomyosarcoma cells, which enter mitosis with 
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unrepaired DNA damage, leading to irreparable DNA damage during mitosis 
incompatible with cell survival.  
PAX3-FOXO1 is sufficient to increase replication stress and is required for 
hypersensitivity to ATR pathway inhibition  
Several factors exist in synthetic lethal relationship with ATR18-26. To identify which of 
the known factors were responsible for sensitivity to ATR inhibition in alveolar 
rhabdomyosarcoma cells, we assessed their presence in rhabdomyosarcoma cell lines and 
their association with ATR inhibitor sensitivity (Extended data Fig. 4). Even though some 
cell lines that were highly sensitive to ATR inhibition also presented reduced expression 
of TP53 or ATM, or high PGBD5 mRNA expression, these associations were not 
statistically significant (Extended data Fig. 4a-b and Fig. 4d-f). In line with MYCN’s 
ability to drive replication stress, high MYCN expression, as measured using western 
immunoblotting, was significantly associated with high ATR inhibitor sensitivity both in 
alveolar and embryonal rhabdomyosarcoma cells (Extended data Fig. 4a and Fig. 4c). 
Intriguingly, the pathognomonic fusion oncogene PAX3-FOXO1 drives MYCN 
expression in alveolar rhabdomyosarcomas31.  Based on this function of PAX3-FOXO1 
and previous reports showing that chimeric transcription factors, such as EWS-FLI1 in 
Ewing sarcoma, can themselves render cells hypersensitive to ATR inhibition through 
induction of replication stress32,33, we hypothesized that PAX3-FOXO1 may contribute 
to replication stress and hypersensitivity to ATR inhibition in alveolar 
rhabdomyosarcomas. To test this, we ectopically expressed PAX3-FOXO1 in 
untransformed mouse myoblast cells (C2C12, Fig. 4a), and three embryonal 
rhabdomyosarcoma cell lines (Extended data Fig. 5a-c). PAX3-FOXO1 expression 
sensitized cells to AZD6738 and BAY-1895344, which was most pronounced in C2C12 
cells (Fig. 4b and Extended data Fig. 5d-g). In line with previous reports, PAX3-FOXO1 
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expression in rhabdomyosarcoma cells was sufficient to induce high MYCN expression 
(Extended data Fig. 5a-c). Interestingly, ectopic PAX3-FOXO1 expression was 
associated with increased phosphorylation of RPA32 at T21, but reduced phosphorylation 
at S33 (Fig. 4a and Extended data Fig. 5a-c). This change in RPA32 phosphorylation was 
also observed in cells treated with hydroxyurea (HU), a potent inducer of replication 
stress, but was not observed when cells were treated with doxorubicin (Doxor.), which 
leads to replication stress-independent DNA damage (Fig. 4a and Extended data Fig. 5a-
c). This differential effect on RPA32 phosphorylation might also be a secondary result 
due to cell cycle blockage in G1, as RPA32 phosphorylation at S33 is cell-cycle 
dependent and accumulates in late S/G229. Consistent with increased replication stress-
induced DNA damage, H2AX phosphorylation increased in cells expressing PAX3-
FOXO1 (Fig. 4c-d).  To test whether PAX3-FOXO1 was required for ATR inhibitor 
hypersensitivity, we inducibly expressed shRNA directed against PAX3-FOXO1 mRNA 
in PAX3-FOXO1-expressing alveolar rhabdomyosarcoma cells. Indeed, shRNA-
mediated repression of PAX3-FOXO1 resulted in reduced sensitivity towards ATR 
inhibitor treatment (Fig. 4e-f), which was accompanied by reduced MYCN expression. 
This indicates that the pathognomonic fusion oncoprotein PAX3-FOXO1 is necessary 
and sufficient for ATR inhibitor sensitivity in alveolar rhabdomyosarcoma cells (Fig. 4e-
f), representing a therapeutically targetable synthetic lethal ATR dependency. 
A genome-wide CRISPR activation screen identifies molecular factors required for 
ATR inhibitor hypersensitivity in alveolar rhabdomyosarcoma cells   
Successful clinical translation of synthetic lethal dependencies depends on knowledge 
about molecular factors influencing sensitivity to targeted therapy. Therefore, we aimed 
to identify factors affecting sensitivity of alveolar rhabdomyosarcoma cells to ATR 
inhibition, even in the presence of PAX3-FOXO1. To identify such factors, we used a 
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genome-wide CRISPR-Cas9-based gene activation screen (CRISPRa) targeting over 
70,000 genomic loci and 20,000 genes34. PAX3-FOXO1-expressing cells were 
genetically engineered to express endonuclease deficient Cas9, transcriptional activation 
complex members and transduced with a single guide RNA (sgRNA) library, as described 
before34. Next, cells were incubated for 9 days in the presence of 750 nM AZD6738 (Fig. 
5a). SgRNAs significantly depleted in cells incubated in the presence of AZD6738 (i.e. 
predicted to induce a negative selective advantage under therapy) were enriched for 
factors promoting cell cycle checkpoint release and replication stress, e.g. MYC 
(Extended data Fig. 6a), in line with the observed PAX3-FOXO1-induced MYCN 
expression and replication stress leading to ATR inhibitor sensitivity (Fig. 1E), and 
consistent with reports in other tumor entities22. SgRNAs whose abundance increased in 
the presence of AZD6738 (i.e. predicted to induce a positive selective advantage under 
therapy), on the other hand, were enriched for FOS gene family members FOSB, FOSL1, 
and FOSL2 (Fig. 5b-c). Efficient induction of FOSB, FOSL1 and FOSL2 mRNA 
expression by single sgRNAs was confirmed using RT-qPCR (Fig. 5d-f). Cells 
expressing FOSB, FOSL1 and FOSL2-targeting sgRNAs and dCas9 showed reduced 
sensitivity to AZD6738 (Fig. 5g-h and Extended data Fig. 6b-c), as evidenced by changes 
in dose-response behavior of cells (Fig. 5g-h), confirming that positive enrichment in our 
CRISPRa screen was due to changes in sensitivity to ATR inhibition. AP-1, a 
transcription complex between JNK and FOS gene family members, is a known 
modulator of DNA damage response35,36, leading us to hypothesize that FOSB, FOSL1 
and FOSL2 may reduce steady-state replication stress in alveolar rhabdomyosarcoma 
cells even in the presence of PAX3-FOXO1 and MYCN. Indeed, CRISPRa-driven FOS 
gene family member expression was sufficient to reduce steady state RPA S33 and T21 
phosphorylation in alveolar rhabdomyosarcoma cells, indicating reduced replication 
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stress (Fig. 5i-j). Thus, FOS gene family members can reduce replication stress, which is 
associated with decreased sensitivity of alveolar rhabdomyosarcoma cells to ATR 
inhibitor treatment. 
ATR inhibition leads to reduced BRCA1 activation and repressed homologous 
recombination in PAX3-FOXO1-expressing rhabdomyosarcoma cells 
We next sought to identify potential mechanisms of ATR inhibition-induced replication 
stress exacerbation and genomic instability in PAX3-FOXO1-expressing alveolar 
rhabdomyosarcoma cells by measuring proteome-wide changes in phosphorylation using 
stable isotope labeling with amino acids in cell culture (SILAC) followed by liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) phospho-proteomic 
analysis of cells incubated in the presence of AZD6738. Short-term AZD6738 incubation 
for two hours significantly reduced phosphorylation of known ATR pathway members 
(Fig. 6a), such as the direct ATR target TP53 S1537. Using a phosphosite-centered tool38, 
we analyzed the activated and repressed pathways after pharmacological ATR inhibition 
(Fig. 6b). As expected, the ATR pathway was the most significantly repressed pathway, 
followed by the ATM and response to UV irradiation pathways. In line with the observed 
accumulation of cells in G2/M phases after ATR inhibition, peptides from the CDK1 
pathway and pathways activated in response to nocodazole, an inhibitor of microtubule 
formation leading to lack of mitotic spindle and M-phase arrest39, were phosphorylated 
at higher degrees after ATR inhibitor treatment (Fig. 6b). Homologous recombination 
(HR) and post-replication repair were among the cellular processes most significantly 
repressed after ATR inhibition (Fig. 6c), supporting our conclusion that the observed 
increase in genomic instability in cells was due to erroneous repair of unresolved 
replication intermediates. A particularly high degree of differential phosphorylation was 
measured in BRCA1 peptides (Fig. 6a). BRCA1 is a known substrate of ATR40, and is 
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involved in HR at sites of replication stress41-43. A cluster of BRCA1 serine residues, 
including S1524, can be phosphorylated by ATR and serve as key regulatory sites for 
BRCA1 activity in DNA damage repair40,44,45. Using western immunoblotting, we tracked 
phosphorylation of one of these residues, BRCA1 S1524, in cells over the course of 
AZD6738 treatment. Increased replication stress in exponentially growing cells was 
accompanied with increased S1524 phosphorylation, which was significantly reduced 
following AZD6738 treatment (Fig. 6d-e), confirming LC-MS/MS-based measurements 
(Fig. 6a). Whereas short-term ATR inhibition led to decreased BRCA1 S1524 
phosphorylation, long-term treatment was also accompanied with decreased total BRCA1 
levels (Fig. 6d-e). Next, we tested whether reduced BRCA1 phosphorylation affected 
BRCA1 activity during HR by measuring HR and NHEJ in cells after incubation with 
AZD6738. Indeed, HR activity, and to a lesser extent NHEJ activity, were significantly 
reduced in cells incubated with AZD6738 (Fig. 6f). Thus, ATR inhibition represses 
BRCA1 activity and HR in rhabdomyosarcoma cells.  
ATR inhibition sensitizes cells to PARP inhibition and cisplatin in vitro  
Based on the observation that ATR inhibition led to reduced BRCA1 activation and 
repressed HR pathway activity in rhabdomyosarcoma cells (Fig. 6), we hypothesized that 
the reduced replication stress-induced DNA damage repair via HR may increase 
dependence on PARP-mediated base excision repair (BER), as observed in BRCA1-
deficient cancers10. Indeed, shRNA-mediated BRCA1 knock down in alveolar 
rhabdomyosarcoma cells with three independent shRNAs led to increased sensitivity to 
PARP inhibition, with IC50 for olaparib changing from 39.4 µM for shGFP-expressing 
cells to 5.01 µM, 7.19 µM and 15.84 µM for three shRNAs targeting BRCA1, 
respectively (Extended data Fig. 7a-b). This suggests that BER is required in 
rhabdomyosarcoma cells in the absence of BRCA1 activity. Consistently, BRCA1 knock 
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down also sensitized rhabdomyosarcoma cells to ATR inhibition (Extended data Fig. 7c). 
We hypothesized that due to its effect on BRCA1 activity, pharmacological ATR 
inhibition could sensitize rhabdomyosarcoma cells to PARP inhibition as well as 
cisplatin, a cytotoxic agent also known to be more effective in the context of HR 
deficiency10. Indeed, significant synergy of combined AZD6738 and olaparib as well as 
combined AZD6738 and cisplatin treatment was detected by Excess over Bliss analysis 
(Fig. 7a-c and Extended data Fig. 7d-i). Thus, ATR inhibition sensitized 
rhabdomyosarcoma cells to olaparib and cisplatin, creating clinically exploitable 
opportunities for combination therapy. 
Combined inhibition of ATR and PARP has synergistic anti-tumor effects in patient-
derived alveolar rhabdomyosarcoma models  
We next sought to explore the effect of single agent ATR inhibition and its combination 
with olaparib in patient-derived PAX3-FOXO1-expressing alveolar rhabdomyosarcoma 
xenografts (PDX). Notably, we used a PAX3-FOXO1-expressing PDX model derived 
from a patient still undergoing treatment of a chemotherapy resistant alveolar 
rhabdomyosarcoma relapse at our hospital at the time the experiments outlined here were 
performed. Histological analysis of the PDX and matching patient tumor confirmed that 
the PDX model adequately reflected alveolar rhabdomyosarcoma histologically and 
expressed PAX3-FOXO1 and MYCN (Fig. 7d). In line with our observations in vitro, 
single-agent AZD6738 or BAY-1895344 treatment led to significant reductions in tumor 
burden over time in mice harboring the alveolar rhabdomyosarcoma PDX (Fig. 7e-f). 
Neither AZD6738 nor BAY-1895344 alone led to significant reduction in mouse weight 
(Extended data Fig. 8), indicating drug tolerability. Addition of olaparib to AZD6738 
treatment significantly potentiated the anti-tumor effects, leading to full regression of the 
PDX (Fig. 7f). Loss of mouse weight after 10 days of combined AZD6738 and olaparib 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 6, 2020. ; https://doi.org/10.1101/2020.12.04.411413doi: bioRxiv preprint 
15 
 
treatment, however, indicated increased toxicity compared to single agent treatment 
(Extended data Fig. 8b). Thus, combined pharmacological inhibition of ATR and PARP 
has synergistic activity against preclinical models of PAX3-FOXO1-expressing alveolar 
rhabdomyosarcomas, which may be clinically translatable.  
Compassionate use of ATR inhibitors in patients with PAX3-FOXO1-expressing 
rhabdomyosarcomas is clinically feasible and tolerable 
Pediatric clinical trials with ATR inhibitors are currently being prepared. Encouraged by 
the promising anti-tumor activity of combined AZD6738 (ceralasertib) and olaparib 
treatment observed in the PDX model (Fig. 7f), which was derived from an 18 year old 
female patient undergoing treatment of a highly chemo-resistant PAX3-FOXO1-
expressing alveolar rhabdomyosarcoma 5th relapse at the Charité University Hospital in 
Berlin, we decided for a compassionate use of ceralasertib and olaparib in this patient. 
Prior to the compassionate use treatment, the patient had been treated according to the 
recommendations of the registry for soft tissue sarcoma and other soft tissue tumors in 
children, adolescents, and young adults (CWS-SoTiSaR). All conventional treatment 
options had been exhausted, while the patient’s tumor continued to progress during 
treatment. We initiated oral treatment with ceralasertib according to dose and schedule 
currently investigated in adult clinical trials (Extended data Fig. 9, NCT03682289, 
NCT03428607, NCT03462342 among others).  Apart from supportive pain medication 
with non-opioid analgesics, no additional drugs were administered throughout the 
duration of treatment. The patient was closely clinically monitored on a bi-weekly basis, 
but standardized tumor imaging was not feasible due to the late stage of disease. Notably, 
the patient reported marked reduction of pain in tumor regions (back and abdomen) from 
7 (severe pain) to 3 (mild pain) on a numeric rating scale of 10 after one week of combined 
ceralasertib and olaparib treatment. Apart from known on-target off-tumor toxicity of 
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ceralasertib on blood counts, in particular thrombocytopenia grade 1 according to the 
Common Terminology Criteria for Adverse Events (CTCAE; Extended data Fig. 9), no 
considerable side effects were observed nor reported by the patient over the course of 
treatment. In parallel, we tested the anti-tumor efficacy of the ATR inhibitor BAY-
1895344 against primary patient-derived cells from another patient with relapsed PAX3-
FOXO1-expressing alveolar rhabdomyosarcoma, hospitalized at the Memorial Sloan 
Kettering Cancer Center in New York (USA). Patient-derived cells were sensitive to 
inhibition of ATR by BAY-1895344 (Extended data Fig. 10a), leading us to begin the 
compassionate use of BAY-1895344 in this patient. The patient received 15 mg of BAY-
1895344 per os twice a day for 3 days followed by 4 days of drug pause for 3 weeks.  
After demonstrating tolerability, doses were increased to 18 mg twice a day (Extended 
data Fig. 10b). The patient refused further assessment using imaging, but reported 
clinically relevant improvement in pain and laboratory signs that may reflect response, 
such as decreased lactate dehydrogenase (LDH) levels (Extended data Fig. 10b). Even 
though both patients progressed within one month after ATR inhibitor treatment, the two 
compassionate use cases presented here provide promising evidence that ATR inhibitors 
ceralasertib and BAY-1895344 may present clinically tolerable and feasible treatment 
options for patients suffering from alveolar rhabdomyosarcomas. 
Discussion 
We have found that PAX3-FOXO1, a pathognomonic fusion oncogene in alveolar 
rhabdomyosarcoma, confers a synthetic lethal dependency on ATR-mediated DNA 
damage repair. Consistent with previous reports of other oncogenic fusion genes inducing 
replication stress in Ewing sarcoma33, expression of PAX3-FOXO1 was sufficient to 
increase replication stress, which required both DNA damage repair and DNA damage 
signaling, resulting in apoptosis if impaired by the selective inhibition of ATR, or ATR-
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pathway members. Both untransformed mouse myoblast cells and rhabdomyosarcoma 
cells engineered to express PAX3-FOXO1, as well as PAX3-FOXO1-expressing 
rhabdomyosarcoma cell lines, accumulated unrepaired DNA damage and underwent 
apoptosis upon treatment with selective inhibitors of ATR signaling. These effects, 
observed specifically in PAX3-FOXO1-expressing rhabdomyosarcoma cells, were 
associated with decreased phosphorylation of BRCA1 and homologous recombination 
activity, and were accompanied by induction of genomic instability, increased G2/M 
accumulation and apoptosis. In turn, single-agent treatment with structurally diverse 
inhibitors of ATR exhibited potent antitumor activity against high-risk patient-derived 
alveolar rhabdomyosarcoma models. Moreover, decreased BRCA1 and homologous 
recombination activity through pharmacological ATR inhibition sensitized cells to PARP 
inhibition. When combined, ATR and PARP inhibitors exhibited strong antitumor 
activity against patient-derived rhabdomyosarcoma models. Lastly, compassionate use of 
ATR inhibitors in two cases of relapsed, PAX3-FOXO1-driven, alveolar 
rhabdomyosarcoma indicated clinical feasibility and tolerability. 
Human cancers require active DNA damage repair for survival. As a result, selective 
inhibitors of ATR-mediated DNA damage repair signaling have been used to target 
tumors with intrinsic deficiencies in DNA repair or high abundance of DNA damage. 
Dissecting the molecular mechanisms of susceptibility to ATR inhibitors has been the 
subject of extensive investigations in the past years46. We and others have found inducers 
of ATR inhibitor susceptibility, such as PGBD5 recombinase activity in embryonal 
tumors21, oncogene-induced replication stress, ATM loss, and TP53 deficiency20,47. Our 
current work revealed a specific synthetic lethal dependency conferred by high steady-
state replication stress in alveolar, PAX3-FOXO1-expressing rhabdomyosarcoma. 
Pharmacological inhibition of DNA damage signaling kinases exhibited a specific 
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response profile, with ATR- and CHK1-selective inhibitors showing enhanced replication 
stress-dependent anti-tumor activity. Notably, CHK1, a downstream target of ATR, is 
inhibited by prexasertib, which is currently being clinically investigated in combination 
with chemotherapy for patients with relapsed rhabdomyosarcoma (NCT04095221). 
Given their varied potency and selectivity, it is possible that other selective DNA damage 
signaling inhibitors can also effectively target replication stress-induced synthetic lethal 
dependencies in rhabdomyosarcoma. In line with replication stress-dependent anti-tumor 
activity of ATR inhibitors, our genome-wide CRISPR-based screen identified potent 
replication stress inducers such as MYC as sensitizers to ATR inhibition. Because ATR 
is also activated by specific DNA structures such DNA-RNA hybrid R-loops, which can 
be the cause of oncogene-induced DNA replication stress33, the apparent selective activity 
of ATR inhibitors in PAX3-FOXO1-expressing cells may also be due to the formation of 
such structures. We provide evidence that PAX3-FOXO1 expression, at least in part, 
contributes to replication stress and hypersensitivity to ATR inhibition, which is 
consistent with previous reports of fusion oncogene-induced replication stress in Ewing 
sarcoma32,33. High MYCN expression was also detected in PAX3-FOXO1-expressing 
cells and was positively associated with ATR inhibitor sensitivity. MYCN has been 
described as a direct target of PAX3-FOXO1 and is itself a potent inducer of replication 
stress48. Thus, MYCN likely also contributes to high replication stress and 
hypersensitivity to ATR inhibition in PAX3-FOXO1-expressing cells. Alternative 
lengthening of telomeres (ALT) is also frequently observed in embryonal 
rhabdomyosarcoma not expressing PAX3-FOXO149-51. Due to the lack of models for 
robust induction of ALT in human cells, we currently cannot assess the contribution of 
ALT to ATR inhibitor sensitivity in rhabdomyosarcoma. Nevertheless, the susceptibility 
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of PAX3-FOXO1-expressing tumors to selective ATR inhibitors is expected to cooperate 
with oncogene-, ALT-associated and other sources of replication stress. 
ATR is essential for intra-S phase and G2/M checkpoint activation13,16,25,52. When 
checkpoints are constitutively active, cells can undergo checkpoint adaptation to continue 
proliferating despite the presence of DNA damage53,54. We anticipate that susceptibility 
to ATR inhibitors may also depend on tumor-specific mechanisms of checkpoint 
adaptation. While little is known about checkpoint adaptation in human cells, CHK1 and 
CDK1 can promote checkpoint adaptation by mediating forced mitotic entry55,56. 
Inhibition of ATR could exacerbate the effect of checkpoint adaptation by suppressing 
checkpoint activation. Consistently, we observed accumulation of cells in G2/M and 
increased activation of CDK1 targets in our phosphoproteomic profiling after ATR 
inhibition. In line with checkpoint adaptation promoting DNA damage accumulation and 
genomic instability54, we observed high degrees of genomic instability in PAX3-FOXO1-
expressing cells treated with ATR inhibitors. Intriguingly, PAX3-FOXO1 can itself 
promote checkpoint adaptation in rhabdomyosarcoma cells through induction of PLK1 
expression, which in turn activates CDK1 and forced mitotic entry57. It is tempting to 
speculate that ATR dependency in PAX3-FOXO1-expressing rhabdomyosarcoma could 
also be due to checkpoint adaptation. 
Even though results of clinical trials with ATR inhibitors in adults have shown promising 
single agent antitumor activity in various tumor entities, many patients progress or relapse 
after some time58,59. Thus, identifying molecular mechanisms of ATR inhibitor resistance 
is of paramount clinical importance, as it may enable the identification of clinical 
biomarkers that help predict ATR inhibitor susceptibility and can be used to monitor 
resistance development. Our genome-wide CRISPRa screen in rhabdomyosarcoma cells 
identified the FOS family of transcription factors as repressors of replication stress, 
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leading to decreased sensitivity towards ATR inhibition in rhabdomyosarcoma cells. 
Apart from their role in DNA damage repair regulation35,36, the FOS gene family are 
known negative regulators of myoblast differentiation and can directly repress MYOD, 
MYOG and PAX7 expression both in primary myoblasts and rhabdomyosarcoma cell60,61, 
suggesting that rhabdomyosarcoma cell differentiation may represent an additional 
mechanism through which FOS gene family members reduce sensitivity to ATR 
inhibition. It remains to be determined, however, how the intrinsic ability to differentiate 
or the pre-existence of cells in different differentiation states contributes to ATR inhibitor 
resistance. It is well described that transitions between differentiation states in cancers 
occurs62, but the underlying mechanisms leading to epigenetic and transcriptional 
reprogramming are still poorly understood. Based on our observations, we anticipate that 
studying trans-differentiation between stable or unstable epigenetic cellular states in 
rhabdomyosarcoma may improve our understanding of rhabdomyosarcoma resistance to 
therapy. 
In conclusion, we here present preclinical evidence and clinical observations supporting 
a molecularly targeted therapeutic option for an aggressive subset of 
rhabdomyosarcomas, for which current treatment options have been exhausted and 
prognosis remains dismal. Our findings warrant the future investigation of ATR inhibitors 
in clinical trials for children with PAX3-FOXO1-expressing alveolar 
rhabdomyosarcoma, the majority of which should be characterized by ATR-signaling 
dependencies. 
Materials and Methods 
Study design 
The purpose of this study was to examine the effects of ATR inhibition in preclinical 
models of rhabdomyosarcoma and identify potential biomarkers to select patients that 
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could benefit from small molecule ATR inhibitor treatment. We first determined the 
inhibitory activity of the ATR inhibitors in rhabdomyosarcoma cell models, and 
compared these cells based on known determinants of ATR inhibition sensitivity, as well 
as PAX3-FOXO1, a molecular feature of alveolar rhabdomyosarcomas. We analyzed the 
effects of AZD6738 treatment on genomic instability (including double strand break 
formation, micronucleation, and apoptosis) and on protein phosphorylation. All in vitro 
experiments were performed in at least three technical replicates in at least two cell 
models of each meolecular rhabdomyosarcoma subgroup (PAX3-FOXO1-expressing vs. 
embryonal rhabdomyosarcoma). Outliers were not excluded unless technical errors were 
present. For the CRISPRa screen, we used only one cell line and at least three independent 
sgRNAs per gene. All sgRNAs of interest were validated in independent experiments. 
For the analysis of phosphoproteomic changes after ATR inhibition, we used three 
independently grown biological replicates of the same rhabdomyosarcoma cell line. For 
in vivo testing, sample size was decided based on previous experience with the models. 
Animals euthanized before the end of the experiment, due to excessive tumor growth or 
loss of body weight, were included in the analysis. For patient use of the drugs, we 
consulted with the company the appropriate dose regimen based on current clinical trials. 
The researchers and patients were not blinded during the experiments. 
Reagents 
All reagents were obtained from Carl Roth (Karlsruhe, Germany) unless otherwise 
indicated. Oligonucleotide primers were obtained from Eurofins Genomics (Luxemburg, 
Luxemburg, Table 1). A list of antibodies and their catalog numbers can be found in Table 
2. AZD6738 (celarasertib) was provided by Astra Zeneca (Cambridge, UK). All drugs 
were dissolved in Dimethylsulfoxid (DMSO) and stored at 10 mM concentrations at -20 
°C. 
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Human PAX3-FOXO1 cDNA was PCR-amplified and isolated from a plasmid gifted by 
Prof. Beat Schäfer. PAX3-FOXO1 cDNA was cloned into pENTR1A (Thermo Fisher) 
using the restriction enzymes SalI and NotI (New England Biolabs), and cloned into a 
pInducer20 (Addgene #44012) using the Gateway strategy and the manufacturer’s 
protocol (Thermo Fisher). pLKO.1 shRNA plasmids targeting BRCA1 
(TRCN0000009823, TRCN0000010305, TRCN0000039834), and control targeting GFP 
(shGFP) were obtained from the RNAi Consortium (Broad Institute). Plasmid containing 
an inducible shRNAs targeting PAX3-FOXO1 (cloned in the pRSI backbone) were a kind 
gift from Prof. Beat Schäfer. 
Cell culture 
Rh41, TE441.T, Kym1 and Rh18 cells were a kind gift from Prof. Simone Fulda. The 
remaining human tumor cell lines were obtained from the American Type Culture 
Collection (ATCC, Manassas, Virginia).  The absence of Mycoplasma sp. contamination 
was determined using a Lonza (Basel, Switzerland) MycoAlert system. Rh4, Rh30, Rh41, 
RD, T174, TE381.T, TE441.T, C2C12, HEK293T, RPE1-hTERT and BJ cell lines were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo Fisher, Waltham, 
Massachusetts, USA) supplemented with 10% fetal calf serum (Thermo Fisher) and 
penicillin/streptomycin (Thermo Fisher). Rh18 and Kym1 cells were cultured in Roswell 
Park Memorial Institute (RPMI)-1640 (Thermo Fisher) supplemented with 10% fetal calf 
serum and penicillin/streptomycin. Twice per week, cells were washed with phosphate-
buffered saline (PBS), incubated in trypsin (Thermo Fisher) for five minutes sedimented 
at 500 g for 5 minutes and a fraction was cultured in fresh media. Cells were kept in 
culture for a maximum of 30 passages. Resuspended cells were counted by mixing 1:1 
with 0.02 % trypan blue in a BioRad (Hercules, CA, USA) TC20 cell counter. 
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Lentivirus were produced as previously described63. In short, HEK293T cells were 
transfected using TransIT-LT1 (Mirus, Madison, Wisconsin, USA) in a 2:1:1 ratio of 
lentiviral plasmid, psPAX2 and pMD2.G plasmids following the TransIT-LT1 
manufacturer’s protocol. Viral supernatant was collected 48h and 72h after transfection, 
pooled, filtered and stored at -80 °C. Cells were transduced for one day in the presence 
of 8µg/mL polybrene (Sigma Aldrich). 
CRISPRa screening and sequencing 
The genome-wide CRISPRa screen was performed as described in Konermann et al.34. 
Briefly, Rh4 cells were transduced with the lentiMPH v2 plasmid (Addgene #89308) and 
selected with hygromycin for 10 days (Thermo Fisher). Next, cells were transduced with 
the sgRNA library at a multiplicity of infection (MOI) of < 0.3, ensuring at least 500 cells 
to be transduced with each sgRNA-encoding plasmid on average. After selection with 
blasticidin (Thermo Fisher) for 7 days, cells were separated in two groups, one group was 
incubated in the presence of AZD6738 at 750 nM concentration and the other group was 
incubated in the presence of DMSO. Genomic DNA was extracted and the sgRNA 
amplified using PCR and barcoded for Illumina sequencing. Sequencing was performed 
on a NextSeq500 with Mid Output, with a read length of 1 x 81bp +8 bp Index and 20% 
PhiX Control v3. Samples were demultiplexed using flexbar64 and analyzed using 
MaGECK65. 
Dependency analysis using DepMap 
To study dependency to DNA damage proteins, we used the dataset CRISPR Avana 20Q2 
publicly available in the online resource DepMap27. Cell lines were grouped by tissue of 
origin, and groups with only one cell line were excluded from the analysis. For 
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rhabdomyosarcoma, we subdivided the group into subgroups in order to differentiate 
alveolar, embryonal and other rhabdomyosarcomas. 
Cell viability 
Cell viability was assessed using CellTiter-Glo (Promega, Madison, Wisconsin, USA). 
Briefly, for CellTiter-Glo measurement, 1,000 cells were seeded in white, flat-bottom, 
96-well plates (Corning, Corning, NY, USA). After 24 hours, drugs were added to the 
medium and cells were incubated for 72 hours. CellTiter-Glo luminescent reagent was 
added according to the manufacturers protocol, and the luminescence signal measured on 
a Glowmax-Multi Detection System (Promega). To evaluate if a combination of drugs is 
synergistic, cells were simultaneously treated with varying concentrations of drugs, and 
cell viability was measured with CellTiter-Glo. Synergism scores were obtained using the 
R package SynergyFinder66. For patient-derived cells, dose-response studies were 
performed using 11 doubling dilutions in triplicate with 100µM, 10µM and 1µM as the 
highest concentration (5uL in 10% DMSO). After cell seeding (45uL), the plates were 
placed in a controlled environment at 37ºC and 5% CO2 for 3 days. Then, 5µL Alamar 
Blue (AB) were added using the Multidrop™ Combi. They were further incubated for 1 
day, and the fluorescence intensity was read on a Cytation 5 Cell Imaging Multi-Mode 
Reader (Biotek). 
Immunoblotting 
Whole-cell protein lysates were prepared by lysing cells in Radioimmunoprecipitation 
assay buffer (RIPA) supplemented with cOmplete Protease inhibitor (Roche, Basel, 
Switzerland) and PhosphStop (Roche). To enrich in nuclear proteins, samples were 
prelysed in a soft lysis buffer (5mM PIPES ph=8.0, 85mM KCl, 0.5%NP-40), followed 
by the lysis with RIPA buffer. Protein concentrations were determined by bicinchoninic 
acid assay (BCA, Thermo Fisher). 10 µg of protein were denatured in Laemmli buffer at 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 6, 2020. ; https://doi.org/10.1101/2020.12.04.411413doi: bioRxiv preprint 
25 
 
95 °C for 5 minutes. Lysates were loaded onto 16%, 10% Tris-Glycin (Thermo Fisher) 
or 3-8% Tris-Acetate gels (Thermo Fisher) for gel electrophoresis depending on the 
protein sizes of interest. Proteins were transferred onto Polyvinylidenfluorid (PVDF) 
membranes (Roche), blocked with 5% dry milk for 1 hour and incubated with primary 
antibodies overnight at 4°C, then secondary antibodies for 1 hour at room temperature. 
Chemiluminescent signal was detected using Enhanced chemiluminescence (ECL) 
Western Blotting Substrate (Thermo Fisher) and a Fusion FX7 imaging system (Vilber 
Lourmat, Marne-la-Vallée, France). Quantification was performed with ImageJ. 
Immunofluorescence 
Cells were grown at the desired confluency on a glass coverslide for 24h (micronuclei 
quantification) and treated with 1000ng/mL doxycycline for another 48h (for the 
corresponding experiment). Cells were washed with PBS three times and fixed for 10 
minutes with 4% paraformaldehyde, washed with PBS three times and permeabilized 
with PBS containing 0.1% Triton-X100. For micronuclei detection, cells were mounted 
on a slide with DAPI-containing mounting media (Vectashield, Vec-H-1000). For 
immunofluorescence, cells were blocked for 40 minutes with 5% BSA in PBS, incubated 
overnight at 4ªC with the primary antibody (yH2AX; Millopore (#05-636), washed three 
times with PBS-T (0.05% Tween-20 in PBS), incubated for 1 hour in the dark at room 
temperature with the secondary antibody (Dianova, 715-096-150), washed three times 
with PBS-T and mounted on a slide with DAPI-containing mounting media. Cells were 
imaged using an ECHO Revolve microscope and quantified using ImageJ. 
RT-qPCR 
RNA from cell lines was extracted using RNeasy mini kit (QIAGEN). Synthesis of cDNA 
was performed using Transcription First Strand cDNA Synthesis kit (Roche). 50 ng of 
cDNA were combined with the corresponding primers (Table 1), and SG qPCR Master 
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Mix (Roboklon, Berlin, Germany), keeping the mixture and cycling conditions 
recommended by the manufacturer. 
Fluorescence-activated cell sorting (FACS) 
For cell cycle analysis, cells were incubated with 5-Ethynyl-2´-deoxyuridine (EdU) for 2 
hours and fluorescent labeling was performed with the Click-IT EdU Alexa Fluor 488 
Flow Cytometry Assay kit (Thermo Fisher), according to the manufacturer’s description. 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed 
using the APO-BrdU TUNEL Assay Kit (Thermo Fisher), according to the 
manufacturer’s descriptions. Cell death was assessed by measuring caspase 3 cleavage 
using a CellEvent Caspase3/7 Green Flow Cytometry kit (Thermo Fisher), according to 
the manufacturer’s descriptions. Stained cells were measured on a BD LSR Fortessa flow 
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). 
DNA damage repair activity assay 
All the plasmids were obtained from Addgene (pDRGFP #26475; pimEJ5GFP #44026 ; 
pCBA-SceI #26477; pCAG-FALSE #89689;pCAGGS-mCherry #41583). The protocol 
was adapted from the plasmid depositors’67,68. Briefly, cells were co-transfected with 
pCBA-SceI and pDRGFP, or pCBA-SceI and pimEJ5GFP to analyze homologous 
recombination and non-homologous end joining activity, respectively. As a negative 
control, pCBA-SceI was substituted with the empty backbone pCAG-FALSE. 
Transfection efficiency was calculated using cells transfected with pCAGGS-mCherry. 
Two days after transfection, cells were trypsinized, washed twice with PBS and 
fluorescence measured with flow cytometry. 
Phosphoproteomics sample preparation 
Rh30 cells were cultured for two weeks in the presence of stable isotope labeling with 
amino acids (SILAC) media  in DMEM, 10% dialysed fetal calf serum, 1% Proline, 1% 
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Glutamine, 0.025% 8Lysine and 10Arginine (“Heavy”) or 0Lysine and 0Arginine 
(“Light”). After labelling, cells were incubated in the presence of AZD6738 750 nM or 
DMSO for two hours in biological triplicates. Cells were harvested, resuspended and 
combined in 400 µL of 8 M urea and 0.1 M Tris-HCl, pH 8. Proteins were reduced in 10 
mM dithiothreitol (DTT) at room temperature for 30 minutes and alkylated with 50 mM 
iodoacetamide (IAA) at room temperature for 30 minutes in the dark. Proteins were first 
digested by lysyl endopeptidase (LysC) (Wako Pure Chemical Industries, Ltd., Osaka, 
Japan) at a protein-to-LysC ratio of 100:1 (w/w) at room temperature for 3 hours. Then, 
the sample solution was diluted to final concentration of 2 M urea with 50 mM ammonium 
bicarbonate (ABC). Trypsin (Promega) digestion was performed at a protein-to-trypsin 
ratio of 100:1 (w/w) under constant agitation at room temperature for 16 hours. Tryptic 
digests corresponding to 200 µg protein per condition were desalted with big C18 Stage 
Tips packed with 10 mg of ReproSil‐Pur 120 C18‐AQ 5 µm resin (Dr. Maisch GmbH, 
Ammerbuch, Germany). Peptides were eluted with 200 µL of loading buffer (80% ACN 
(v/v) and 6% TFA (v/v). Phosphopeptides were enriched using a microcolumn tip packed 
with 0.5 mg of TiO2 (Titansphere, GL Sciences, Tokyo, Japan)69. The TiO2 tips were 
equilibrated with 20 μL of the loading buffer via centrifugation at 100 g. 50 μL of the 
sample solution was loaded on a TiO2 tip via centrifugation at 100 g and this step was 
repeated until the sample solution was loaded. The TiO2 column was washed with 20 μL 
of the loading buffer, followed by 20 μL of washing buffer (50% ACN (v/v) and 0.1% 
TFA (v/v)). The bound phosphopeptides were eluted using successive elution with 30 μL 
of elution buffer 1 (5% ammonia solution), followed by 30 μL of elution buffer 2 (5% 
piperidine)70. Each fraction was collected into a fresh tube containing 30 μL of 20% 
formic acid. 3 μL of 100% formic acid was added to further acidify the samples. The 
phosphopeptides were desalted with C18 Stage Tips prior to nanoLC-MS/MS analysis.  
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Peptides were separated on a 2 m monolithic column (MonoCap C18 High Resolution 
2000 (GL Sciences), 100 µm internal diameter x 2,000 mm at a flow rate of 300 nL/min 
with a 5 to 95 % acetonitrile gradient on an EASY-nLC II system (Thermo Fisher 
Scientific). 240-min gradient was performed for phosphoproteome analyses. A Q 
Exactive plus instrument (Thermo Fisher Scientific) was operated in the data dependent 
mode with a full scan in the Orbitrap followed by top 10 MS/MS scans using higher-
energy collision dissociation (HCD). For whole proteome analyses, the full scans were 
performed with a resolution of 70,000, a target value of 3x106 ions and a maximum 
injection time of 20 ms. The MS/MS scans were performed with a 17,500 resolution, a 
1x106 target value and a 20 ms maximum injection time. For phosphoproteome analyses, 
the full scans were performed with a resolution of 70,000, a target value of 3x106 ions 
and a maximum injection time of 120 ms. The MS/MS scans were performed with a 
35,000 resolution, a 5x105 target value and a 160 ms maximum injection time. Isolation 
window was set to 2 and normalized collision energy was 26. 
Raw data were analyzed and processed using MaxQuant (v1.5.1.2)71. Search parameters 
included two missed cleavage sites, fixed cysteine carbamidomethyl modification, and 




oxidation, N-terminal protein acetylation, and asparagine/glutamine deamidation. In 
addition, phosphorylation of serine, threonine, and tyrosine were searched as variable 
modifications for phosphoproteome analysis. The peptide mass tolerance was 6 ppm for 
MS scans and 20 ppm for MS/MS scans. Database search was performed using 
Andromeda72 against uniprot-human 2014-10 with common contaminants. False 
discovery rate (FDR) was set to 1% at both peptide spectrum match (PSM) and protein 
level. The ‘re-quantify’ and ‘match between runs’ functions were enabled. 
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Phosphorylation sites were ranked according to their phosphorylation localization 
probabilities (P) as class I (P > 0.75), class II (0.75 > P > 0.5) and class III sites (P < 0.5), 
and only class I sites were used for further analyses. Data normalization was performed 
using the default settings of the R package DEP73. In short, peptides not identified in at 
least two replicates in both conditions were removed. Intensity values were normalized 
based on the variance stabilizing transformation, and missing values were imputed using 
random draws from a Gaussian distribution centered around a minimal value (q= 0.01). 
For pathway enrichment analysis, we used a single sample gene set enrichment analysis 
(ssGSEA) as previously described38, ranking genes according to their fold change. For 
gene ontology (GO) analysis, we followed the ClusterProfiler R package74. P-values were 
calculated using hypergeometric distribution (one-sided Fisher exact test) and corrected 
for multiple comparisons (Holm-Bonferroni method), selecting phosphopeptides with a 
fold change>1 or <-1 and a FDR<0.01, and reporting the top 10 GO terms enriched in the 
subset. 
Patient-derived xenograft (PDX) treatment 
The establishment of PDX models was conducted as previously described75 in 
collaboration with Experimental Pharmacology & Oncology GmbH (EPO, Berlin, 
Germany). All experiments were conducted according to the institutional animal 
protocols and the national laws and regulations. Tumor fragments from 
rhabdomyosarcoma patients were transplanted into NOD.Cg-Prkdcscid 
Il2rgtm1Sug/JicTac mice (Taconic, Rensselaer, NY, USA). Tumor growth was 
monitored with caliper measurements. Tumor volume was calculated with the formula 
length x width^2 / 2.  PDX were serially transplanted in mice at least three times prior to 
the experiments. Mice were randomized into four groups with at least 3 mice to receive 
AZD6738 (50 mg/kg day, oral), cisplatin (2mg/kg twice weekly), olaparib (50 mg/kg day, 
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oral), a combination of AZD6738 and either cisplatin or olaparib, or vehicle. For in vivo 
treatment, AZD6738 was dissolved in DMSO at 62.5 mg/ml and mixed 1:10 in 40% 
propylene glycol and 50% sterile water, resulting in a final AZD6738 concentration of 
6.25 mg/ml. Cisplatin was dissolved in phosphate-buffered saline and administered 
intraperitoneally. Olaparib was dissolved in 4% DMSO, 30% polyethylene glycol 300 
and sterile water. For the BAY-1895344 study, mice were administered 40mg/kg body 
weight on a 3 days on/ 4 days off regime twice daily (orally). BAY-1895344 was 
dissolved in 60% polyethylene glycol 400, 10% ethanol and 30% water to a 4mg/ml 
solution. Mice were sacrificed by cervical dislocation once the tumor volume exceeded 
2,000 mm3 or body weight loss was higher than 10%. Solutions in which the drugs were 
dissolved were used as vehicle controls respectively. 
Compassionate AZD6738 and BAY-1895344 use  
Oral treatment with AZD6738, olaparib and BAY-1895344 were provided according to 
a compassionate-use protocol. Drugs were provided by AstraZeneca and Bayer, 
respectively. Treatment regimens were based on regimens currently tested in clinical 
trials, and the patients/guardians provided written informed consent to participate in the 
compassionate use protocols and this case report. There was no commercial support for 
this study. Tumor material was collected according to the clinical protocol. Peripheral 
blood samples were collected in vacutainer tubes ± Ethylenediaminetetraacetic acid 
(EDTA) or ± Heparin. Simultaneous PET/MRI was performed with a 3T MRI/PET 
Magnetom Biograph mMR hybrid  system  (Siemens  Healthcare,  Erlangen,  Germany;  
software  vB20P),  featuring  avalanche  photodiode and total imaging matrix coil 
technology. MR parameters included: MQ- Gradients: 45 mT/m maximum gradient 
amplitude; 200 T/m/s maximum gradient slew rate; LSO crystal; 4.3 mm  transverse  
spatial  resolution  at  FWHM  at  1  cm;  15.0  kcps/MBq  sensitivity  at  center;  13.8  
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kcps/MBq at 10 cm off-center. [18F]FDG was administered intravenously using a weight-
adapted activity based on recommendations provided by the European Association of 
Nuclear Medicine (EANM). A test of blood glucose level was mandatory to assure that 
blood glucose level was ≤8.3 mmol/l. The PET scan was performed after an uptake time 
of ≥55 minutes in supine position from vertex to toes (3D mode; bed overlap, 53.3%). 
Among others, acquired MRI-sequences included axial T1 volumetric interpolated 
breath-hold examination (VIBE) using two-point Dixon fat-water separation (Dixon-
VIBE) images  following bodyweight-adapted administration of gadolinium-based MRI 
contrast agent (Gadovist®, Bayer, Leverkusen, Germany). Within the PET/MRI data 
generated, all areas with pathologically increased tracer uptake were identified and 
volumetrically assessed using the corresponding MRI-sequence. The MRI sequences 
were acquired on a MAGNETOM Skyra (Siemens) after application of 6.9 ml 
gadolinium-based MRI contrast agent (Bayer, Leverkusen, Germany). Tumor foci were 
measured in axial T1 volumetric interpolated breath-hold examination (VIBE) using two-
point Dixon fat-water separation (Dixon-VIBE) images. Ultrasonography was performed 
with a GE logiq e9 R6 instrument (General Eclectics, Boston, USA). 
Statistical analysis 
All statistical tests were done using GraphPrism7 (student’s two-sided t-test) or were part 
of the R package used for the analysis (MAGeCK, DEP, CePa). 
 
Extended data 
Extended Data Fig. 1. Alveolar rhabdomyosarcoma cells express ATR and depend on 
expression of ATR/CHK1 pathway members. 
Extended Data Fig. 2. PAX3-FOXO1-expressing alveolar rhabdomyosarcoma cells are 
hypersensitive to pharmacological ATR pathway inhibition. 
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Extended Data Fig. 3. Pharmacological ATR inhibition exacerbates replication stress 
and leads to genomic instability, apoptosis and cell cycle disruption. 
Extended Data Fig. 4. Molecular factors associated with ATR inhibitor sensitivity in 
rhabdomyosarcoma cells. 
Extended Data Fig. 5. Ectopic expression of PAX3-FOXO1 increases sensitivity to ATR 
inhibition in rhabdomyosarcoma cells. 
Extended Data Fig. 6. FOSB, FOSL1 and FOSL2 expression induces resistance to ATR 
inhibition in rhabdomyosarcoma cells. 
Extended Data Fig. 7. ATR inhibition synergizes with cisplatin and olaparib in 
rhabdomyosarcoma cell lines.    
Extended Data Fig. 8. Combined treatment of mice with AZD6738 and olaparib has no 
remarkable toxicity in mice harboring alveolar rhabdomyosarcoma PDX models. 
Extended Data Fig. 9. Compassionate use of AZD6738 and olaparib in a patient 
suffering from relapsed metastasized PAX3-FOXO1-expressing alveolar 
rhabdomyosarcomas. 
Extended Data Fig. 10. Compassionate use of BAY-1895344 in a patient suffering from 
relapsed metastasized PAX3-FOXO1-expressing alveolar rhabdomyosarcomas. 
Table 1. Oligonucleotide primers. 
Table 2. Antibodies. 
 
References 
1 Ognjanovic, S., Linabery, A. M., Charbonneau, B. & Ross, J. A. Trends in childhood 
rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 115, 
4218-4226, doi:10.1002/cncr.24465 (2009). 
2 Douglass, E. C. et al. A specific chromosomal abnormality in rhabdomyosarcoma. 
Cytogenet Cell Genet 45, 148-155 (1987). 
3 Douglass, E. C. et al. Variant translocations of chromosome 13 in alveolar 
rhabdomyosarcoma. Genes Chromosomes Cancer 3, 480-482 (1991). 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 6, 2020. ; https://doi.org/10.1101/2020.12.04.411413doi: bioRxiv preprint 
33 
 
4 Keller, C. et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: 
cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18, 2614-2626, 
doi:10.1101/gad.1244004 (2004). 
5 Perkins, S. M., Shinohara, E. T., DeWees, T. & Frangoul, H. Outcome for children with 
metastatic solid tumors over the last four decades. PLoS One 9, e100396, 
doi:10.1371/journal.pone.0100396 (2014). 
6 Crist, W. et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13, 610-
630, doi:10.1200/JCO.1995.13.3.610 (1995). 
7 Shern, J. F. et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a 
landscape of alterations affecting a common genetic axis in fusion-positive and fusion-
negative tumors. Cancer Discov 4, 216-231, doi:10.1158/2159-8290.CD-13-0639 
(2014). 
8 Cheung, N. K. & Dyer, M. A. Neuroblastoma: developmental biology, cancer genomics 
and immunotherapy. Nat Rev Cancer 13, 397-411, doi:10.1038/nrc3526 (2013). 
9 Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating 
genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068 
(1997). 
10 Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic 
strategy. Nature 434, 917-921, doi:10.1038/nature03445 (2005). 
11 Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA 
mutation carriers. N Engl J Med 361, 123-134, doi:10.1056/NEJMoa0900212 (2009). 
12 Kotsantis, P., Petermann, E. & Boulton, S. J. Mechanisms of Oncogene-Induced 
Replication Stress: Jigsaw Falling into Place. Cancer Discov 8, 537-555, 
doi:10.1158/2159-8290.CD-17-1461 (2018). 
13 Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: ensuring faithful 
duplication of a challenging genome. Nat Rev Mol Cell Biol 18, 622-636, 
doi:10.1038/nrm.2017.67 (2017). 
14 Bass, T. E. et al. ETAA1 acts at stalled replication forks to maintain genome integrity. 
Nat Cell Biol 18, 1185-1195, doi:10.1038/ncb3415 (2016). 
15 Haahr, P. et al. Activation of the ATR kinase by the RPA-binding protein ETAA1. Nat 
Cell Biol 18, 1196-1207, doi:10.1038/ncb3422 (2016). 
16 Buisson, R., Boisvert, J. L., Benes, C. H. & Zou, L. Distinct but Concerted Roles of ATR, 
DNA-PK, and Chk1 in Countering Replication Stress during S Phase. Mol Cell 59, 1011-
1024, doi:10.1016/j.molcel.2015.07.029 (2015). 
17 Feijoo, C. et al. Activation of mammalian Chk1 during DNA replication arrest: a role for 
Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 154, 
913-923, doi:10.1083/jcb.200104099 (2001). 
18 Fokas, E. et al. Targeting ATR in DNA damage response and cancer therapeutics. Cancer 
Treat Rev 40, 109-117, doi:10.1016/j.ctrv.2013.03.002 (2014). 
19 Kwok, M. et al. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage 
response defects by targeting the ATR pathway. Lancet 385 Suppl 1, S58, 
doi:10.1016/S0140-6736(15)60373-7 (2015). 
20 Kwok, M. et al. ATR inhibition induces synthetic lethality and overcomes 
chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 
127, 582-595, doi:10.1182/blood-2015-05-644872 (2016). 
21 Henssen, A. G. et al. Therapeutic targeting of PGBD5-induced DNA repair dependency 
in pediatric solid tumors. Sci Transl Med 9, doi:10.1126/scitranslmed.aam9078 (2017). 
22 Foote, K. M., Lau, A. & Nissink, J. W. Drugging ATR: progress in the development of 
specific inhibitors for the treatment of cancer. Future Med Chem 7, 873-891, 
doi:10.4155/fmc.15.33 (2015). 
23 Morgado-Palacin, I. et al. Targeting the kinase activities of ATR and ATM exhibits 
antitumoral activity in mouse models of MLL-rearranged AML. Sci Signal 9, ra91, 
doi:10.1126/scisignal.aad8243 (2016). 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 6, 2020. ; https://doi.org/10.1101/2020.12.04.411413doi: bioRxiv preprint 
34 
 
24 Middleton, F. K. et al. Common cancer-associated imbalances in the DNA damage 
response confer sensitivity to single agent ATR inhibition. Oncotarget 6, 32396-32409, 
doi:10.18632/oncotarget.6136 (2015). 
25 Karnitz, L. M. & Zou, L. Molecular Pathways: Targeting ATR in Cancer Therapy. Clin 
Cancer Res 21, 4780-4785, doi:10.1158/1078-0432.CCR-15-0479 (2015). 
26 Chen, T. et al. Development of pharmacodynamic biomarkers for ATR inhibitors. Mol 
Oncol 9, 463-472, doi:10.1016/j.molonc.2014.09.012 (2015). 
27 Meyers, R. M. et al. Computational correction of copy number effect improves specificity 
of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet 49, 1779-1784, 
doi:10.1038/ng.3984 (2017). 
28 Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat Cell 
Biol 16, 2-9, doi:10.1038/ncb2897 (2014). 
29 Vassin, V. M., Anantha, R. W., Sokolova, E., Kanner, S. & Borowiec, J. A. Human RPA 
phosphorylation by ATR stimulates DNA synthesis and prevents ssDNA accumulation 
during DNA-replication stress. J Cell Sci 122, 4070-4080, doi:10.1242/jcs.053702 
(2009). 
30 Zhang, C. Z. et al. Chromothripsis from DNA damage in micronuclei. Nature 522, 179-
184, doi:10.1038/nature14493 (2015). 
31 Gryder, B. E. et al. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers 
BET Bromodomain Vulnerability. Cancer Discov 7, 884-899, doi:10.1158/2159-
8290.CD-16-1297 (2017). 
32 Nieto-Soler, M. et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. 
Oncotarget 7, 58759-58767, doi:10.18632/oncotarget.11643 (2016). 
33 Gorthi, A. et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 
repair in Ewing sarcoma. Nature 555, 387-391, doi:10.1038/nature25748 (2018). 
34 Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-
Cas9 complex. Nature 517, 583-588, doi:10.1038/nature14136 (2015). 
35 Tomicic, M. T. et al. Delayed c-Fos activation in human cells triggers XPF induction and 
an adaptive response to UVC-induced DNA damage and cytotoxicity. Cell Mol Life Sci 
68, 1785-1798, doi:10.1007/s00018-010-0546-9 (2011). 
36 Christmann, M. & Kaina, B. Transcriptional regulation of human DNA repair genes 
following genotoxic stress: trigger mechanisms, inducible responses and genotoxic 
adaptation. Nucleic Acids Res 41, 8403-8420, doi:10.1093/nar/gkt635 (2013). 
37 Lakin, N. D., Hann, B. C. & Jackson, S. P. The ataxia-telangiectasia related protein ATR 
mediates DNA-dependent phosphorylation of p53. Oncogene 18, 3989-3995, 
doi:10.1038/sj.onc.1202973 (1999). 
38 Krug, K. et al. A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell 
Proteomics 18, 576-593, doi:10.1074/mcp.TIR118.000943 (2019). 
39 Downing, K. H. Structural basis for the interaction of tubulin with proteins and drugs that 
affect microtubule dynamics. Annu Rev Cell Dev Biol 16, 89-111, 
doi:10.1146/annurev.cellbio.16.1.89 (2000). 
40 Gatei, M. et al. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related 
kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo 
assessment using phospho-specific antibodies. J Biol Chem 276, 17276-17280, 
doi:10.1074/jbc.M011681200 (2001). 
41 Helt, C. E., Cliby, W. A., Keng, P. C., Bambara, R. A. & O'Reilly, M. A. Ataxia 
telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target 
specificities in response to different forms of DNA damage. J Biol Chem 280, 1186-1192, 
doi:10.1074/jbc.M410873200 (2005). 
42 Kang, Y. et al. Protein phosphatase 5 is necessary for ATR-mediated DNA repair. 
Biochem Biophys Res Commun 404, 476-481, doi:10.1016/j.bbrc.2010.12.005 (2011). 
43 Jeggo, P. A., Pearl, L. H. & Carr, A. M. DNA repair, genome stability and cancer: a 
historical perspective. Nat Rev Cancer 16, 35-42, doi:10.1038/nrc.2015.4 (2016). 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 6, 2020. ; https://doi.org/10.1101/2020.12.04.411413doi: bioRxiv preprint 
35 
 
44 Beckta, J. M. et al. Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced 
homologous recombination, and a compensatory increase in non-homologous end 
joining. Oncotarget 6, 27674-27687, doi:10.18632/oncotarget.4876 (2015). 
45 Cortez, D., Wang, Y., Qin, J. & Elledge, S. J. Requirement of ATM-dependent 
phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 
286, 1162-1166, doi:10.1126/science.286.5442.1162 (1999). 
46 Lecona, E. & Fernandez-Capetillo, O. Targeting ATR in cancer. Nat Rev Cancer 18, 586-
595, doi:10.1038/s41568-018-0034-3 (2018). 
47 Menezes, D. L. et al. A synthetic lethal screen reveals enhanced sensitivity to ATR 
inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res 
13, 120-129, doi:10.1158/1541-7786.MCR-14-0240 (2015). 
48 Mercado, G. E. et al. Identification of PAX3-FKHR-regulated genes differentially 
expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a 
biologically relevant target. Genes Chromosomes Cancer 47, 510-520, 
doi:10.1002/gcc.20554 (2008). 
49 Ohali, A. et al. Different telomere maintenance mechanisms in alveolar and embryonal 
rhabdomyosarcoma. Genes Chromosomes Cancer 47, 965-970, doi:10.1002/gcc.20600 
(2008). 
50 Liau, J. Y. et al. Comprehensive screening of alternative lengthening of telomeres 
phenotype and loss of ATRX expression in sarcomas. Mod Pathol 28, 1545-1554, 
doi:10.1038/modpathol.2015.114 (2015). 
51 Kleideiter, E. et al. Telomerase activity in cell lines of pediatric soft tissue sarcomas. 
Pediatr Res 54, 718-723, doi:10.1203/01.PDR.0000086901.29111.2A (2003). 
52 Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat Rev 
Mol Cell Biol 9, 616-627, doi:10.1038/nrm2450 (2008). 
53 Kato, T. A., Okayasu, R. & Bedford, J. S. Signatures of DNA double strand breaks 
produced in irradiated G1 and G2 cells persist into mitosis. J Cell Physiol 219, 760-765, 
doi:10.1002/jcp.21726 (2009). 
54 Deckbar, D. et al. Chromosome breakage after G2 checkpoint release. J Cell Biol 176, 
749-755, doi:10.1083/jcb.200612047 (2007). 
55 Gheghiani, L., Loew, D., Lombard, B., Mansfeld, J. & Gavet, O. PLK1 Activation in Late 
G2 Sets Up Commitment to Mitosis. Cell Rep 19, 2060-2073, 
doi:10.1016/j.celrep.2017.05.031 (2017). 
56 Syljuåsen, R. G., Jensen, S., Bartek, J. & Lukas, J. Adaptation to the ionizing radiation-
induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and 
Polo-like kinase 1 kinases. Cancer Res 66, 10253-10257, doi:10.1158/0008-5472.CAN-
06-2144 (2006). 
57 Kikuchi, K. et al. Cell-cycle dependent expression of a translocation-mediated fusion 
oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet 10, 
e1004107, doi:10.1371/journal.pgen.1004107 (2014). 
58 Dillon, M. T. et al. PATRIOT: A phase I study to assess the tolerability, safety and 
biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor 
(AZD6738) as a single agent and in combination with palliative radiation therapy in 
patients with solid tumours. Clin Transl Radiat Oncol 12, 16-20, 
doi:10.1016/j.ctro.2018.06.001 (2018). 
59 Thomas, A. et al. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan 
in Patients With Advanced Solid Tumors. J Clin Oncol 36, 1594-1602, 
doi:10.1200/JCO.2017.76.6915 (2018). 
60 Pedraza-Alva, G., Zingg, J. M. & Jost, J. P. AP-1 binds to a putative cAMP response 
element of the MyoD1 promoter and negatively modulates MyoD1 expression in dividing 
myoblasts. J Biol Chem 269, 6978-6985 (1994). 
61 Fleischmann, A., Jochum, W., Eferl, R., Witowsky, J. & Wagner, E. F. 
Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by 
the Fos protooncogene. Cancer Cell 4, 477-482, doi:10.1016/s1535-6108(03)00280-0 
(2003). 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 6, 2020. ; https://doi.org/10.1101/2020.12.04.411413doi: bioRxiv preprint 
36 
 
62 van Groningen, T. et al. A NOTCH feed-forward loop drives reprogramming from 
adrenergic to mesenchymal state in neuroblastoma. Nat Commun 10, 1530, 
doi:10.1038/s41467-019-09470-w (2019). 
63 MacArthur, I. C. et al. Prohibitin promotes de-differentiation and is a potential 
therapeutic target in neuroblastoma. JCI Insight 5, doi:10.1172/jci.insight.127130 (2019). 
64 Dodt, M., Roehr, J. T., Ahmed, R. & Dieterich, C. FLEXBAR-Flexible Barcode and 
Adapter Processing for Next-Generation Sequencing Platforms. Biology (Basel) 1, 895-
905, doi:10.3390/biology1030895 (2012). 
65 Li, W. et al. MAGeCK enables robust identification of essential  genes from genome-
scale CRISPR/Cas9 knockout  screens. Genome Biol 15, 554, doi:10.1186/s13059-014-
0554-4 (2014). 
66 He, L. et al. Methods for High-throughput Drug Combination Screening and Synergy 
Scoring. Methods Mol Biol 1711, 351-398, doi:10.1007/978-1-4939-7493-1_17 (2018). 
67 Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes homology-
directed repair of DNA damage in mammalian cells. Genes Dev 13, 2633-2638, 
doi:10.1101/gad.13.20.2633 (1999). 
68 Bennardo, N., Cheng, A., Huang, N. & Stark, J. M. Alternative-NHEJ is a mechanistically 
distinct pathway of mammalian chromosome break repair. PLoS Genet 4, e1000110, 
doi:10.1371/journal.pgen.1000110 (2008). 
69 Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, 
pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2, 
1896-1906, doi:10.1038/nprot.2007.261 (2007). 
70 Kyono, Y., Sugiyama, N., Imami, K., Tomita, M. & Ishihama, Y. Successive and 
selective release of phosphorylated peptides captured by hydroxy acid-modified metal 
oxide chromatography. J Proteome Res 7, 4585-4593, doi:10.1021/pr800305y (2008). 
71 Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized 
p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 
26, 1367-1372, doi:10.1038/nbt.1511 (2008). 
72 Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant 
environment. J Proteome Res 10, 1794-1805, doi:10.1021/pr101065j (2011). 
73 Zhang, X. et al. Proteome-wide identification of ubiquitin interactions using UbIA-MS. 
Nat Protoc 13, 530-550, doi:10.1038/nprot.2017.147 (2018). 
74 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing 
biological themes among gene clusters. OMICS 16, 284-287, doi:10.1089/omi.2011.0118 
(2012). 
75 Timme, N. et al. Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against 




We thank Experimental Pharmacology & Oncology GmbH for technical support. We 
thank Astra Zeneca for providing AZD6738 (ceralasertib) and olaparib for the 
compassionate use, as well as Emma Dean, Alan Lau, Andrew Pierce and Bienvenú 
Loembé for the fruitful discussions. We thank Bayer for providing BAY-1895344 and 
support for preclinical studies using that drug. Funding: The project that gave rise to 
these results received the support of a fellowship from ”la Caixa” Foundation (ID 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 6, 2020. ; https://doi.org/10.1101/2020.12.04.411413doi: bioRxiv preprint 
37 
 
100010434). The fellowship code is LCF/BQ/EU18/11650037. A.G.H. is supported by 
the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 
398299703 and the Wilhelm Sander Stiftung. This research was financially supported by 
the Charité 3R, Charité - Universitätsmedizin Berlin. A.G.H. is supported by the German 
Cancer Consortium (DKTK). A.G.H. is a participant in the BIH-Charité Clinical Scientist 
Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of 
Health. M.V.O. is supported by Cannonball Kids’ cancer and the NIH/NCI via K12 
CA184746 and P30 CA008748.  This work was supported by the Deutsche Krebshilfe 
(German Cancer Aid) – 70113870  and 70113871. We thank the patients and their parents 
for granting access to the tumor specimen and clinical information that were analyzed in 
this study. Author Contributions: H.D.G. and A.G.H. contributed to the study design, 
collection and interpretation of the data and wrote the manuscript. H.D.G., Y.B., J.v.S., 
G.I., K.I., N.T., R.C.G., I.M., F.P., C.Y.C., J.S., C.F., and B.L. performed experiments, 
analyzed data and reviewed this manuscript. H.D.G., K.He. and K.Ha. performed the 
analysis of the CRISPR screening. V.B., D.G., and J.R. collected and prepared PDX 
samples. A.W., A.E., M.Sc., G.S., P.H., M.K., P.M., M.Se., A.L., J.H.S., and M.O. 
contributed to study design. A.G.H. led the study design, to which all authors contributed.  
Competing interests: A.M.W. is employed by Bayer AG. A.G.H. has received research 
funding from Bayer AG. Data availability: All data is available upon request.  
Materials & Correspondence  





.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 





Fig. 1. Alveolar rhabdomyosarcoma cells depend on ATR and are hypersensitive to 
pharmacological ATR inhibition. (a) ATR dependency scores in cell lines from a 
variety of cancer entities obtained from CRISPR (Avana) 20Q2 (Alveolar 
rhabdomysarcoma, ARMS, red; other rhabdomyosarcoma and embryonal 
rhabdomyosarcoma, ERMS, blue). (b) Dose-response curves of cell viability for ARMS 
cell lines (red) and ERMS (blue) treated with the ATR inhibitor AZD6738 compared to 
non-transformed cells (grey; n=3). (c) Area under the curve (AUC) of dose-response 
curves shown in (b) (P=0.041 for ARMS vs ERMS; P=0.035 for ARMS vs Ctrl). (d) 
Dose-response curves of cell viability for ARMS cell lines (red) and ERMS (blue) treated 
with the ATR inhibitor BAY-1895344 compared to non-transformed cells (grey; n=3). 
(e) AUC the dose-response curves shown in (c) (P=0.162 for ARMS vs ERMS;  P= 0.025 
for ARMS vs Ctrl; two-sided student’s t-test; error bars represent standard error of the 
mean).   
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Fig. 2.  Alveolar rhabdomyosarcoma cells present higher baseline genomic 
instability than embryonal rhabdomyosarcoma despite similar DNA repair 
efficiencies. (a) Western immunoblot for RPA32 phosphorylation in rhabdomyosarcoma 
cell lines (Histone 3 serves as a loading control). (b) Quantification of RPA32 S33 
(P=0.025) and T21 (P=0.208) signal intensity. (c) Representative images of 
rhabdomyosarcoma cells stained with DAPI (arrows indicate micronuclei, squares in top 
right corners indicate higher magnification). (d) Quantification of the fraction of 
rhabdomyosarcoma cells containing at least one micronucleus (P=1.4x10-4). (e) 
Quantification of HR (P=0.071) and NHEJ activity (P=0.516) in rhabdomyosarcoma cell 
lines (two-sided student’s t-test; error bars represent standard error of the mean).   
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 




Fig. 3. Pharmacological ATR inhibition exacerbates replication stress and leads to 
genomic instability, apoptosis and cell cycle disruption in alveolar 
rhabdomyosarcoma cells. (a) Western immunoblot of RPA32 phosphorylation in Rh4 
cells treated with ATR inhibitor AZD6738 (750 nM). (b) Fraction of micronucleated cells 
after incubation with AZD6738 (750 nM) for 72 hours (n=3, with at least 40 nuclei 
counted per condition; n=5, for samples with less than 40 nuclei per image; from left to 
right, P=7.1x10-4, P=4.6x10-4, P=1.7x10-4 and P=0.009). (c) Cell cycle phase distribution 
as measured using flow cytometry analysis of EdU and propidium iodide-labeled 
rhabdomyosarcoma cells treated with AZD6738 compared to DMSO-treated cells (n=3). 
(d) Unrepaired double strand breaks (DSBs) measured by TUNEL in cells treated with 
AZD6738 (750 nM) for 72 hours (n=3; from left to right, P=6.0x10-6, P=6.5x10-6, 
P=0.489 and P=0.450).  (e) Fraction of apoptotic cells treated with AZD6738 (750 nM), 
as measured by cleaved caspase 3 staining (n=3; from left to right, P=2.3x10-9, P=5.4x10-
6, P=0.062 and P=0.054). (f) Fraction of hyperploid/aneuploid rhabdomyosarcoma cells 
treated with AZD6738 (750 nM) (n=3; from left to right, P=3.2x10-4, P=5.6x10-5, 
P=0.010 and P=0.080; two-sided student’s t-test; error bars represent standard error of 
the mean).   
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Fig. 4. PAX3-FOXO1 is sufficient and required for hypersensitivity to ATR 
inhibition in myoblast cells. (a) Western immunoblot of PAX3-FOXO1, RPA T21 and 
S33 phosphorylation in C2C12 after induction of PAX3-FOXO1 expression with 
doxycycline (1000 ng/ml for 48 hours) and treatment with AZD6738 (750nM) compared 
to doxorubicin (doxor.) and hydroxyurea (HU) treated cells. (b) Dose-response curves of 
cell viability for C2C12 cells after ectopic expression of PAX3-FOXO1 and incubation 
with AZD6738 (n=3). (c) Representative images of H2AX phosphorylation in C2C12 
cells after ectopic expression of PAX3-FOXO1, as measured using immunofluorescence. 
(d) Quantification of the H2AX phosphorylation immunofluorescence signal in C2C12 
cells after ectopic expression of PAX3-FOXO1 (P=9.57x10-26). (e) Western immunoblot 
of PAX3-FOXO1 and MYCN in Rh4 cells after doxycycline-induced (1000ng/mL) 
expression of shRNAs targeting PAX3-FOXO1 compared to scrambled shRNA control 
for 48h. (f) Dose-response curves for Rh4 after doxycycline-induced (1000ng/mL) 
expression of shRNAs targeting PAX3-FOXO1 compared to scrambled shRNA control 
and treated with AZD6738 (n=3; two-sided student’s t-test; error bars represent standard 
error of the mean).  
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Fig. 5. A genome-wide CRISPR-based activation screen identifies molecular 
modifiers of sensitivity to ATR inhibition in PAX3-FOXO1-expressing alveolar 
rhabdomyosarcoma cells. (a) Schematic representation of the genome-wide CRISPRa 
screen experimental design. (b) Waterfall plot showing the positive robust rank 
aggregation (RRA) score of sgRNAs in Rh4 cells incubated in the presence of AZD6738 
for 9 days compared to DMSO treated cells as analyzed using MaGECK. (c) Relative 
abundance of sgRNAs targeting FOS family members FOSB, FOSL1 and FOSL2 in cells 
in the presence of AZD6738. (d-f) FOSB (d, P=4.7x10-4, P=2.9x10-6 and P=5.1x10-9), 
FOSL1 (e, P=1.2x10-7, P=1.6x10-8 and P=2.2x10-10) and FOSL2 (f, P=4.2x10-5, P=0.400 
and P=0.430) mRNA expression measured using RT-qPCR in cells expressing dCas9, 
lentiMPH and sgRNAs targeting FOSB, FOSL1 or FOSL2 (n=3). (g) Representative 
dose-response cell viability curves of cells stably expressing dCas9, lentiMPH and 
sgRNAs targeting FOSB treated with the ATR inhibitor AZD6738. (h) AUC of dose-
response curves in cells stably expressing dCas9, lentiMPH and sgRNAs targeting FOSB, 
FOSL1 and FOSL2 treated with the ATR inhibitor AZD6738 (n=3, P=0.029, P=0.034 
and P=0.165). (i) Western immunoblot of RPA32 S33 and T21 phosphorylation in cells 
expressing sgRNAs targeting FOS family members FOSB, FOSL1 or FOSL2. (j) 
Quantification of RPA32 phosphorylation compared to the corresponding non-targeting 
control, for S33 (P=0.058, 0.181, 0.113 and 0.091, respectively) and T21 (P=0.044, 
6.43x10-4,1.82x10-3 and 0.012, respectively; two-sided student’s t-test; error bars 
represent standard error of the mean).  
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Fig. 6. Pharmacological ATR inhibition leads to reduced BRCA1 activation and 
repressed homologous recombination in alveolar rhabdomyosarcoma cells. (a) 
Volcano plot showing relative changes in phospho-peptide abundance in PAX3-FOXO1-
expressing Rh30 cells after 2 hours of incubation with AZD6738 (750 nM) measured 
using LC-MS/MS proteomics (red, known ATR targets; dotted line indicating a false 
discovery rate of 0.001). (b) Volcano plot showing relative enrichment of molecular 
pathways in which differential phospho-peptide abundance was observed in cells treated 
with AZD6738 (750 nM) compared to DMSO-treated cells (dotted line indicating a false 
discovery rate of 0.05). (c) Cellular processes significantly enriched in differentially 
abundant phospho-peptides. (d-e) Western immunoblotting of BRCA1 pSer1524 and 
total BRCA1 in Rh30 (d) and Rh4 (e) cells during the course of AZD6738 treatment 
(histone 3 serves as loading control). (f) Relative activity of HR and NHEJ in Rh4 and 
Rh30 cells after incubation with 750nM AZD6738 (From left to right, P=0.003, 
P=1.7x10-4, P=2.7x10-6 and P=2.1x10-6; two-sided student’s t-test; error bars represent 
standard error of the mean).   
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Fig. 7. ATR inhibition sensitizes patient-derived alveolar rhabdomyosarcoma 
xenografts to PARP inhibition in vivo. (a) Excess over Bliss analysis of combined 
treatment with olaparib and AZD6738 in Rh4 cells (n=3). (b) Excess over Bliss analysis 
of combined treatment with cisplatin and AZD6738 in Rh4 cells. (c) Bliss score for four 
rhabdomyosarcoma cell lines treated with AZD6738 combined with olaparib or cisplatin. 
(d) Representative histological images and western immunoblot for PAX3-FOXO1 and 
MYCN for the alveolar rhabdomyosarcoma patient-derived xenograft (PDX) model used. 
(e) Tumor volume over time of mice harboring the alveolar rhabdomyosarcoma PDX 
model subcutaneously xenografted and treated with BAY-1895344  twice daily by oral 
gavage at 40mg/kg body weight per day on a 3 days on/4 days off schedule as compared 
to vehicle control treated mice (n=7 mice per group; top, timeline of the drug schedule). 
(f) Tumor volumes over time of mice harboring the alveolar rhabdomyosarcoma PDX 
model subcutaneously xenografted and treated with AZD6738, olaparib or both 
AZD6738 and olaparib compared to vehicle control treated mice  (n=4 mice per group; 
bottom, excess over Bliss additivity for each treatment timepoint, **P<0.01; two-sided 
student’s t-test; error bars represent standard deviations).  
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